While blocking the PD1/PD-L1 axis has proven effective in disrupting tumor immune tolerance across various cancers, high PD-L1 expression has also been linked to increased tumor-infiltrating lymphocyte levels and poorer survival in HPV-independent CC (64–66). Here, PDCD1 is linked to cancer.